ERBB2 and breast cancer: Notably, preliminary results from early phase clinical trials testing novel anti-HER2 antibody-drug conjugates (ADCs) in advanced breast cancer patients harboring HER2-low expression (1 + or 2+ by IHC in the absence of HER2 gene amplification by ISH) are challenging this notion11,12.